Key result
Beta-blockers possessing intrinsic sympathomimetic activity (ISA) showed the smallest mean increase in triglycerides and an increase in HDL-cholesterol compared to other beta-blockers.
Why the study?
Do beta-blockers with intrinsic sympathomimetic activity (ISA) improve plasma lipid profiles compared to nonselective and beta 1-selective beta-blockers?
Do beta-blockers with intrinsic sympathomimetic activity (ISA) improve plasma lipid profiles compared to nonselective and beta 1-selective beta-blockers?
Beta-blockers with intrinsic sympathomimetic activity, such as pindolol, exhibit a more favorable lipid profile by minimizing triglyceride increases and increasing HDL-cholesterol compared to other beta-blockers.
No takes yet. Share an insight, caveat, or question.
ISA beta-blockers may favor lipid profiles versus alternatives; leaves open outcome impact in prospective trials.
P. van Brummelen (1983) conducted a review in Beta-blocker-induced changes in plasma lipids. Beta-blockers possessing intrinsic sympathomimetic activity (ISA) vs. Nonselective and beta 1-selective beta-blockers was evaluated on Changes in plasma lipids (triglycerides and HDL-cholesterol). Beta-blockers possessing intrinsic sympathomimetic activity (ISA) showed the smallest mean increase in triglycerides and an increase in HDL-cholesterol compared to other beta-blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: